Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.77, read 2026-11-05
Ethical passes the values gate
Price120.79 USD
Fair value188.50
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-21Read Distribution142.70-15.4% to today ✓Markup gives way to Distribution after an 87% rise in 16 weeks
2026-07-02Read Markup76.17+58.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Twist Bioscience Corporation holds its Distribution at $120.79. The statistical read favours the sellers, held for 14 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 14 days
Price at the screen
$120.79
Valuation
N/A trailing · -356.45 forward price to earnings
Values screen
PASS· score 70.0
Beta
2.22
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
11.77%
Below 33%
Interest-bearing debt is just 11.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
8.47%
Below 33%
Cash held in interest-bearing accounts and securities is 8.5% of assets, under the one-third limit.
Pass
Receivables
37.40%
Below 49%
Money owed to the company is 37.4% of assets, under the 49% limit.
Pass
Revenue purity
3.02%
Below 5%
Only 3.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Twist Bioscience clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 12%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TWST's ethical verdict changes
Today TWST passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 36% discount to our $188.50 fair value, 23.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 35.9% discount to the base estimate.
Where our models see it going: fair-value estimate $188.50, with a range of $60.40 to $215.00, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Synthetic DNA Business Trades Above Fair Value
Twist Bioscience makes the synthetic genes that drug developers and researchers rely on to speed up work in therapeutics and diagnostics. The business is expanding revenue 19 percent a year, yet it still loses 20 percent on every dollar of sales and posts an 18 percent negative return on equity. At 93.85 dollars the shares sit just above our 92 dollar fair value, leaving almost no margin of safety and a forward multiple of minus 123 times.
Analysts see the same picture. Their median target matches our fair value exactly, and the opportunity rating remains none despite an ethical screen that clears cleanly. The company supplies a genuine need, yet the current price already prices in far more progress than the cash-flow record supports.
High fixed costs and the long road to consistent profits keep execution risk elevated. A modest revenue miss or slower adoption in any one end market could quickly widen the gap between price and underlying value. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TWST trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-07Distribution$120.79+0.1%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-06Distribution$120.61-15.4%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Distribution$142.58+1.6%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Distribution$140.30-1.7%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
2026-10-28Distribution$142.70+0.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 63% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 59% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter.
2026-10-14Markup$159.78-3.6%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 74% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter.
2026-10-02Markup$165.83+10.5%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 74% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64. Insiders have been net sellers over the past quarter.
2026-09-15Markup$150.06+29.7%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 29.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 74% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64.
2026-08-15Markup$115.67+51.9%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 51.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 74% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 97%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $64.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
